Novel Targets of Chemotherapeutic Drugs that Trap Protein on DNA
DNA 上捕获蛋白质的化疗药物新靶点
基本信息
- 批准号:8878499
- 负责人:
- 金额:$ 16.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-03-10 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAzacitidineBinding ProteinsBiochemicalBiologicalBreast CarcinomaCell physiologyCellsClinicClinicalClinical TrialsColorectal CancerComplexDNADNA AdductsDNA Modification MethylasesDNA TopoisomerasesDecitabineDoseDoxorubicinDrug TargetingDrug effect disorderDrug usageEffectivenessEtoposideFundingFutureGenesGoalsLeadMalignant NeoplasmsMalignant neoplasm of cervix uteriMethodsMutateMutationNucleic AcidsPharmaceutical PreparationsPoisonProteinsProteomicsRNARNA BindingSmall Interfering RNASolid NeoplasmSpecificitySpliceosomesTOP1 geneTOP2A geneTestingTopoisomeraseValidationadductcovalent bonddrug mechanismdrug sensitivityhuman DNAimprovedinsightirinotecanmRNA Exportnew therapeutic targetnovelnovel strategiespublic health relevanceresearch studysmall moleculesuccesstooltumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Some very potent chemotherapeutics used in the clinic function by stabilizing covalent protein-DNA adducts formed as obligatory intermediates in normal cellular function. Despite the demonstrated effectiveness of these drugs, there has been no effort to systematically identify all targets of drugs in this class. Our proposal describes a novel approach that combines stringent enrichment of covalent protein adducts upon drug treatment with unbiased proteomics to identify and discover drug targets. Using this approach, we have confirmed known targets of topotecan and etoposide, and we have identified novel targets of these drugs, thereby establishing the power of this approach as a discovery tool. We propose to apply this approach to identify the targets of six chemotherapeutic drugs that function by this mechanism: etoposide, doxorubicin, topotecan, decitabine (5-aza-dC), azacitidine (5-aza-C) and olaparib, and to validate these targets. Success in these experiments will identify new targets of drugs in current use, and establish a general approach for determining mechanisms of drug action to enable future identification of novel drug-target pairs.
描述(由申请人提供):临床上使用的一些非常有效的化疗药物通过稳定共价蛋白质-DNA加合物发挥作用,该加合物是正常细胞功能中的必需中间体。尽管这些药物的有效性已得到证实,但还没有努力系统地确定这类药物的所有靶点。我们的建议描述了一种新的方法,结合严格的药物治疗后的共价蛋白加合物的富集与公正的蛋白质组学,以确定和发现药物靶点。使用这种方法,我们已经证实了已知的拓扑替康和依托泊苷的目标,我们已经确定了这些药物的新目标,从而建立了这种方法作为发现工具的力量。我们建议应用这种方法来确定通过这种机制发挥作用的六种化疗药物的靶点:依托泊苷,阿霉素,拓扑替康,地西他滨(5-aza-dC),阿扎胞苷(5-aza-C)和奥拉帕尼,并验证这些靶点。这些实验的成功将确定目前使用的药物的新靶点,并建立确定药物作用机制的通用方法,以使未来能够识别新的药物靶点对。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nancy Maizels其他文献
Nancy Maizels的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nancy Maizels', 18)}}的其他基金
Mechanism-based targeting of bacterial topoisomerases
基于机制的细菌拓扑异构酶靶向
- 批准号:
9243114 - 财政年份:2016
- 资助金额:
$ 16.8万 - 项目类别:
Novel Targets of Chemotherapeutic Drugs that Trap Protein on DNA
DNA 上捕获蛋白质的化疗药物新靶点
- 批准号:
9031087 - 财政年份:2015
- 资助金额:
$ 16.8万 - 项目类别:
A Novel Platform for Rapid Development for Anti-WNV Antibodies
快速开发抗西尼罗河病毒抗体的新平台
- 批准号:
8301089 - 财政年份:2011
- 资助金额:
$ 16.8万 - 项目类别:
相似国自然基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Serial monitoring of circulating cell-free tumor DNA as measured by duplex sequencing in older patients with acute myeloid leukemia who receive azacitidine+venetoclax +/- immune checkpoint blockade
通过双重测序对接受阿扎胞苷维奈托克/免疫检查点阻断的老年急性髓系白血病患者的循环游离肿瘤 DNA 进行连续监测
- 批准号:
10337831 - 财政年份:2021
- 资助金额:
$ 16.8万 - 项目类别:
Precision Medicine for Myeloid Malignancies with 5-Azacitidine
5-阿扎胞苷用于骨髓恶性肿瘤的精准医学
- 批准号:
422236 - 财政年份:2020
- 资助金额:
$ 16.8万 - 项目类别:
Fellowship Programs
Precision Medicine for Myeloid Malignancies with 5-Azacitidine
5-阿扎胞苷用于骨髓恶性肿瘤的精准医学
- 批准号:
417283 - 财政年份:2019
- 资助金额:
$ 16.8万 - 项目类别:
Studentship Programs
Beyond Azacitidine: Investigating new therapeutic targets for the treatment of Myelodysplastic Syndrome
超越阿扎胞苷:研究治疗骨髓增生异常综合征的新治疗靶点
- 批准号:
nhmrc : GNT1163815 - 财政年份:2019
- 资助金额:
$ 16.8万 - 项目类别:
Project Grants
Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine
阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化
- 批准号:
nhmrc : GNT1128984 - 财政年份:2017
- 资助金额:
$ 16.8万 - 项目类别:
Project Grants
Clonal Evolution in Myelodysplasia and Acute Myeloid Leukaemia following Azacitidine
阿扎胞苷后骨髓增生异常和急性髓系白血病的克隆进化
- 批准号:
nhmrc : 1128984 - 财政年份:2017
- 资助金额:
$ 16.8万 - 项目类别:
Project Grants
Azacitidine耐性機序の解明に基づく新たな急性白血病治療戦略の確立
阐明阿扎胞苷耐药机制建立急性白血病治疗新策略
- 批准号:
25461435 - 财政年份:2013
- 资助金额:
$ 16.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
- 批准号:
8195498 - 财政年份:2012
- 资助金额:
$ 16.8万 - 项目类别:
Phase II trial of Azacitidine plus Deferasirox in higher risk Myelodysplastic Syndromes (MDS)
阿扎胞苷加地拉罗司治疗高危骨髓增生异常综合征 (MDS) 的 II 期试验
- 批准号:
243003 - 财政年份:2011
- 资助金额:
$ 16.8万 - 项目类别:
Fellowship Programs
PET Imaging of GVHD and GVL after treatment with Azacitidine
阿扎胞苷治疗后 GVHD 和 GVL 的 PET 成像
- 批准号:
8567974 - 财政年份:
- 资助金额:
$ 16.8万 - 项目类别: